Amadix
Company

Last deal

$2.5M

Amount

Grant

Stage

19.01.2022

Date

5

all rounds

$8.1M

Total amount

General

About Company
Amadix develops breakthrough cancer diagnosis products to solve unmet medical needs in oncology.

Industry

Sector :

Subsector :

Also Known As

Advanced Marker Discovery

founded date

01.01.2010

Number of employees

Company Type

For Profit

Last funding type

Grant

IPO status

Private

Description

The company's most advanced product, Colofast, is a non-invasive screening signature for colorectal cancer and advanced adenoma diagnosis in blood. Amadix's team consists of industry veterans with expertise in oncology diagnostics, pharmaceuticals, biotechnology, and intellectual property. The company also has independent board members with international profiles and experience in oncology and diagnostics. Amadix's mission is to extend people's lives by developing disruptive technologies for early cancer detection in blood, avoiding the complications of existing invasive procedures.
Contacts

Phone number

Social url